Clinical Trial Update: Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating ivacaftor in cystic fibrosis patients using ataluren for nonsense mutations has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)
• ataluren (ataluren)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Cystic Fibrosis | Phase 4 | Status: COMPLETED | Results posted: 2019-07-19